Skip to main content
    R

    Regenxbio Inc (RGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.32
    -0.32 (-4.19%)

    Market Cap: $505.18M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Regenxbio Inc (RGNX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Regenxbio reported revenue of $170.44M for the fiscal year ended Dec 31, 2025, up 104.5% from the year before. That year, net income was -$193.88M with a net margin of -113.8%, operating cash flow was -$123.96M and free cash flow was -$126.38M. The quarter ended Sep 30, 2026 had revenue of $9.16M and net income of -$40.74M.

    Revenue and Margins

    The operating margin was -94.6% in the fiscal year ended Dec 2025, the lowest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $4.59M, a compound annual rate of 49.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$170.44M+104.5%100.0%-94.6%-113.8%
    Dec 2024$83.33M-7.7%106.0%-280.0%-272.5%
    Dec 2023$90.24M-19.9%58.8%-297.1%-292.0%
    Dec 2022$112.72M-76.0%51.6%-233.2%-248.7%
    Dec 2021$470.35M+204.3%89.5%34.0%27.2%
    Dec 2020$154.57M+338.7%71.9%-77.1%-72.0%
    Dec 2019$35.23M-83.9%76.6%-422.9%-268.9%
    Dec 2018$218.50M+2002.4%95.6%40.3%45.7%
    Dec 2017$10.39M+126.5%83.6%-730.2%-704.0%
    Dec 2016$4.59MN/A79.1%-1423.8%-1372.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$170.44M$83.33M$90.24M$112.72M$470.35M$154.57M$35.23M$218.50M$10.39M$4.59M
    Cost of revenue$0-$5.00M$37.21M$54.55M$49.26M$43.39M$8.24M$9.68M$1.71M$959.00K
    Gross profit$170.44M$88.33M$53.03M$58.18M$421.08M$111.17M$26.99M$208.82M$8.68M$3.63M
    Research and development$228.30M$208.52M$232.27M$242.45M$181.44M$166.29M$124.19M$83.87M$57.22M$45.48M
    Operating income-$161.20M-$233.35M-$268.13M-$262.88M$159.98M-$119.23M-$149.00M$88.10M-$75.89M-$65.34M
    Net income-$193.88M-$227.10M-$263.49M-$280.32M$127.84M-$111.25M-$94.73M$99.94M-$73.17M-$62.97M
    EBITDA-$150.98M-$221.10M-$250.10M-$244.91M$176.10M-$105.47M-$140.09M$101.78M-$71.38M-$62.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$9.16M$108.02M$6.39M$30.34M$29.73M$21.36M$89.01M$21.21M$24.20M$22.30M$15.62M$22.21M
    Gross profit$9.16M$108.02M$6.39M$30.34M$29.73M$21.36M$89.01M$26.21M$24.20M$22.30M$15.62M$10.97M
    Operating income-$35.53M$29.26M-$83.36M-$57.64M-$52.41M-$63.28M$12.13M-$51.37M-$62.08M-$56.04M-$63.86M-$63.90M
    Net income-$40.74M$22.71M-$90.05M-$67.15M-$61.94M-$70.87M$6.08M-$51.19M-$59.60M-$52.99M-$63.33M-$62.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $47.90M exceeded cash and equivalents by $13.43M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$453.03M$465.99M$573.97M$833.27M$1.11B$708.16M$497.91M$543.81M$198.68M$172.73M
    Current assets$281.28M$278.00M$334.97M$415.98M$518.83M$531.20M$345.03M$337.91M$168.00M$93.37M
    Cash and equivalents$34.47M$57.53M$34.52M$96.95M$345.21M$338.43M$69.51M$75.56M$46.66M$24.84M
    Total liabilities$350.30M$206.34M$262.23M$317.07M$349.61M$330.41M$47.71M$34.97M$15.65M$10.99M
    Short-term debt$47.90M$7.90M$7.07M$6.00M$1.75M$2.50M$2.42MN/AN/AN/A
    Shareholder equity$102.73M$259.65M$311.74M$516.20M$764.30M$377.75M$450.20M$508.85M$183.03M$161.74M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$466.04M$386.62M$341.89M$453.03M$525.20M$581.03M$490.93M$465.99M$519.11M$569.38M$629.22M$573.97M
    Total liabilities$318.00M$314.85M$320.81M$350.30M$363.75M$367.35M$216.73M$206.34M$217.70M$221.11M$238.55M$262.23M
    Cash and equivalents$95.80M$36.49M$15.23M$34.47M$58.80M$79.56M$130.10M$57.53M$56.62M$57.77M$112.97M$34.52M
    Shareholder equity$148.04M$71.77M$21.08M$102.73M$161.45M$213.68M$274.20M$259.65M$301.42M$348.27M$390.67M$311.74M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$123.96M-$173.13M-$218.41M-$207.49M$218.88M-$54.06M-$107.70M$104.65M-$57.99M-$48.56M
    Capital expenditures$2.41M$2.44M$9.96M$30.72M$84.17M$26.87M$11.72M$13.28M$7.16M$8.15M
    Free cash flow-$126.38M-$175.56M-$228.37M-$238.21M$134.70M-$80.93M-$119.42M$91.37M-$65.15M-$56.71M
    Share repurchasesN/AN/AN/AN/A$379.00K$0$0$619.00K$445.00K$60.00K
    Investing cash flow-$15.87M$103.45M$190.94M-$11.93M-$406.64M$122.76M$93.56M-$279.36M-$4.79M$19.39M
    Financing cash flow$116.77M$92.68M-$34.97M-$28.84M$195.25M$200.21M$8.38M$204.44M$84.60M$119.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$38.61M-$62.24M-$76.19M-$52.29M-$55.96M-$49.34M$33.63M-$31.62M-$40.55M-$45.50M-$55.45M-$40.76M
    Capital expenditures$194.00K$760.00K$1.24M$508.00K$491.00K$391.00K$1.02M$1.08M$326.00K$474.00K$557.00K$1.13M
    Free cash flow$38.41M-$63.00M-$77.42M-$52.80M-$56.45M-$49.73M$32.60M-$32.70M-$40.88M-$45.97M-$56.01M-$41.89M
    Last 12 quarters

    Frequently Asked Questions About RGNX

    What is Regenxbio's annual revenue?

    Regenxbio reported revenue of $170.44M for the fiscal year ended Dec 31, 2025.

    How fast is Regenxbio's revenue growing?

    Revenue was up 104.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.8%.

    Is Regenxbio profitable?

    No. Regenxbio reported net income of -$193.88M for the fiscal year ended Dec 31, 2025, with a net margin of -113.8%.

    How much free cash flow does RGNX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$123.96M minus capital expenditures of $2.41M produced free cash flow of -$126.38M.

    How much debt does Regenxbio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $47.90M and cash and equivalents of $34.47M.